Stockwinners Market Radar for November 02, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:14 EDT Cathie Wood's ARK Investment bought 106.8K shares of Exact Sciences today

19:18 EDT Enviva narrows FY22 adjusted EBITDA view to $240M-$260M from $230M-$270M - Sees FY22 CapEx $255M-$265M.

19:04 EDT Interactive Brokers chairman sells $3.2M in common stock - In a regulatory filing, Interactive Brokers disclosed that its Chairman Thomas Peterffy sold 40K shares of common stock on October 31 in a total transaction size of $3.2M.

18:03 EDT Steel Dynamics selects Columbus, Mississippi, as location for aluminum mill - Steel Dynamics announced the selection of Columbus, Mississippi, as the location for the company's greenfield recycled aluminum flat rolled mill. Final site determination is subject to the anticipated receipt of necessary permits and continued state and local government support. The company believes the aluminum flat rolled mill itself will create 700 positions, and that opportunities for indirect job growth of over 250 positions can be created from customers and other support service providers. The planned $1.9B aluminum flat rolled mill is designed to have an annual production capacity of 650,000 tons of finished products, serving the sustainable beverage packaging, automotive, and common alloy industrial sectors. The rolling mill is currently expected to begin operations in mid-2025. The company's focus on decarbonization will also be applied to this aluminum operation, including plans to use a significant amount of pre- and post-consumer aluminum scrap in its production process.

17:49 EDT Mereo BioPharma receives noncompliance notification from Nasdaq - Mereo BioPharma announced that it received a notification letter from the Listing Qualifications Department of Nasdaq notifying the company that its American Depositary Shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of Nasdaq. This notification letter does not result in the immediate delisting of the company's ADSs, and the ADSs will continue to trade, uninterrupted on the Nasdaq Global Market, under the symbol (MREO).

17:46 EDT Marathon Digital produces record 615 bitcoin in October - Marathon Digital published unaudited bitcoin production and miner installation updates for October. "October was the most productive month in Marathon's history both in terms of hash rate growth and bitcoin production," said Fred Thiel, Marathon's chairman and CEO. "The energization of approximately 32,000 of our miners during the month allowed us to increase our hash rate approximately 84% from approximately 3.8 exahashes per second at September 30 to approximately 7.0 exahashes per second at November 1. By successfully growing our hash rate and maintaining uptime, we were able to produce a record 615 bitcoin in October. With S19 XPs now being delivered and new facilities under construction, we believe we are well positioned to continue building on our recent momentum to reach 23 exahashes per second in 2023."

17:42 EDT eBay jumps 8% to $41.00 after Q3 results beat, FY22 EPS guidance raised

17:38 EDT Deutsche Bank raises prime lending rate to 7% from 6.25% - Deutsche Bank announced that its New York Branch, Deutsche Bank New York, and its affiliate Deutsche Bank Trust Company Americas have increased their prime lending from 6.25% to 7.00% effective tomorrow, November 3, 2022.

17:34 EDT HSBC raises prime, reference rate to 7% from 6.25%, effective November 3 - HSBC Bank USA, N.A., and its affiliates announced that they have raised their prime and reference rate to 7.00% from 6.25%, effective November 3.

17:30 EDT U.S. Bancorp raises prime lending rate to 7% from 6.25%, effective November 3

17:27 EDT Teekay Corp. CFO Vince Lok to retire - Teekay Corp. announced Vince Lok's retirement as Teekay's executive VP and CFO effective January 1, 2023 after nearly 30 years with the company, including the past 16 years as Teekay's Group CFO. Upon Lok's retirement, Brody Speers, VP, finance and treasurer, will be assuming Lok's responsibilities, along with continuing to oversee Teekay's finance, accounting and tax teams. Lok has agreed to stay on as an advisor through the end of 2023 to help ensure a transition as well as support the company's strategic initiatives.

17:23 EDT PNC Financial raises prime lending rate to 7.00% from 6.25% - PNC Bank, N.A. announced an increase in its prime lending rate. The new rate of 7.00% is effective tomorrow, Nov. 3, 2022.

17:19 EDT Chord Energy sees Q4 total volumes 170-175 Mboe/d

17:15 EDT Plains All American provides update on capital allocation framework - The company said, "Plains has made significant progress on strengthening its financial position and continues to execute on its long-term goals of generating meaningful Free Cash Flow, maintaining capital discipline, improving financial flexibility, and increasing returns of capital to equity holders via both distribution growth and opportunistic equity repurchases. Plains has achieved leverage below the mid-point of its targeted leverage range well ahead of expectations entering 2022 and now anticipates exiting the year with a leverage ratio of approximately 3.8x. Given the progress made on deleveraging, solid financial and operating performance, and confidence in the long-term outlook of the business, we are providing the following multi-year capital allocation and financial framework: Management currently intends to recommend to the Board of Directors of PAA GP Holdings LLC ("the Plains Board") an annualized increase of $0.20 to PAA's and PAGP's fourth-quarter 2022 distribution payable in February 2023 (one quarter earlier than our standard beginning-of-the-year annual budgeting process), which would increase the annualized rate from $0.87 to $1.07 per common unit and Class A share. Beyond 2023, as part of its standard annual review process, management anticipates targeting annualized common distribution increases of approximately $0.15 per unit each year until reaching a targeted Common Unit Distribution Coverage Ratio of approximately 160%. Maintaining capital discipline, enhancing financial flexibility and achieving mid-BBB/Baa credit ratings remain top priorities; management anticipates leverage migrating below the low-end of the targeted 3.75x - 4.25x range in 2023. Opportunistic unit repurchases will remain a component of our long-term capital allocation framework."

17:11 EDT Sun Life Financial raises quarterly dividend to 72c from 69c per share - The dividend is payable December 30, 2022 to shareholders of record at the close of business on November 23, 2022.

17:10 EDT Revolve Group, Muus Collective sign strategic partnership - Revolve Group announced the signing of a strategic partnership with Griffin Gaming Partners-backed entertainment studio, Muus Collective, to create a fashion-centered Web3 mobile gaming experience that aims to revolutionize how consumers engage with fashion. Expected to launch in 2023, the experience will feature digital playable renderings of select fashion and beauty items from REVOLVE and FWRD.

17:08 EDT Associated Banc-Corp raises prime rate to 7% from 6.25%, effective November 2

17:01 EDT Huntington Ingalls boosts quarterly dividend - HII announced that its board has declared a quarterly cash dividend of $1.24 per share, a 6c increase over the $1.18 per share dividend paid in each of the prior four quarters. The $1.24 per share dividend will be payable on December 9 to shareholders of record as of the close of business on November 25.

17:01 EDT Quotient says reverse stock split effective Wednesday - Quotient Limited announced that a reverse split of its ordinary shares, nil par value, at a ratio of 1-for-40 became effective following close of trading on the Nasdaq Global Market today. The Company's Ordinary Shares will begin trading on a split-adjusted basis when the market opens on November 3, 2022 under the existing trading symbol, "QTNT." The reverse stock split is primarily intended to bring the Company into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq Global Market. The new CUSIP number for the Ordinary Shares following the reverse stock split is G73268149. As a result of the reverse stock split, every forty shares of the Company's Ordinary Shares issued and outstanding was automatically reclassified into one Ordinary Share. The reverse stock split did not modify any rights or preferences of the Ordinary Shares. Shareholders holding Ordinary Shares through a brokerage account will have their Ordinary Shares automatically adjusted to reflect the 1-for-40 reverse stock split. It is not necessary for shareholders holding Ordinary Shares in certificated form to exchange their existing share certificates for new share certificates of the Company in connection with the reverse stock split, although stockholders may do so if they wish. No fractional shares will be issued in connection with the reverse split. The Company's transfer agent will aggregate all fractional shares held by the Company's shareholders into whole shares and arrange for them to be sold on the open market at prevailing prices. In lieu of fractional shares, shareholders will receive a cash payment equal to their allocable share of the total proceeds of these sales.

17:00 EDT Qualcomm sees low-double digits handset volume declines for 2022 - "Given the uncertainty caused by the macroeconomic environment, we are updating our guidance for calendar year 2022 3G/4G/5G handset volumes from a year-over-year mid-single-digit percentage decline, to a low double-digit percentage decline," Qualcomm said. "The rapid deterioration in demand and easing of supply constraints across the semiconductor industry have resulted in elevated channel inventory. Due to these elevated levels, our largest customers are now drawing down on their inventory, negatively impacting the mid-point of our EPS guidance for the first quarter of fiscal 2023 by approximately ($0.80). This is the primary driver of the variance relative to our prior expectations."

16:54 EDT Porch Group appoints Shawn Tabak as CFO - Porch Group announced the appointment of Shawn Tabak as Chief Financial Officer CFO effective November 9. Marty Heimbigner, Porch Group's current Chief Financial Officer, will remain with the Company for a transitional period in a supporting role."I couldn't be more thrilled to welcome Shawn to Porch Group. With his strategic background, specifically within the technology industry, we are confident that he is well suited to help drive our company forward and create additional value for our customers, employees, and shareholders," said Matt Ehrlichman, CEO, Chairman and Founder of Porch Group. "On behalf of our Board of Directors and the entire Porch Group team, I would also like to thank Marty for his leadership over the last several years."

16:53 EDT Regions Bank raises prime lending rate to 7% from 6.25% - Regions Bank announced it is increasing the Regions prime lending rate to 7.00% from 6.25%, effective Thursday, Nov. 3.

16:51 EDT APA Corp. raising annual dividend to $1.00 per share

16:48 EDT Rayonier announces acquisitions in U.S. South - Rayonier announced the company has entered into two separate agreements to acquire approximately 172,400 acres of high-quality commercial timberlands located in Texas, Georgia, Alabama, and Louisiana for an aggregate purchase price of approximately $474 million from Manulife Investment Management, a timberland investment manager. The Acquisitions comprise well-stocked and highly productive timberlands located in some of the strongest timber markets in the U.S. South. Approximately 80% of the Acquisitions consist of fee ownership, and the remaining 20% consist of a long-term lease. The Acquisitions are subject to customary closing conditions and expected to close in the fourth quarter of 2022. Rayonier expects to finance the Acquisitions with cash on hand and the proceeds from incremental borrowings through the Farm Credit System. "The acquisitions announced today underscore our commitment to improving our portfolio quality and sustainable yield through disciplined growth," said David Nunes, President and CEO. "It is rare to come across a collection of premier quality timberland assets with such a strong fit to our existing portfolio. In addition to complementing our southern portfolio, we expect that these acquisitions will generate a strong cash yield from timber operations, which will enhance our cash flow profile, quality of earnings, and market positioning as the leading pure-play timberland REIT. In sum, we are thrilled to be adding these properties to our southern portfolio and look forward to managing them for long-term value creation."

16:45 EDT WWE sees FY22 adjusted OIBDA at upper end of $370M-$385M range - The company states: "In February, the Company issued Adjusted OIBDA guidance of $360 - $375 million for the full year 2022. In August, the Company raised its guidance to $370 - $385 million. Based on performance through the first nine months of the year as well as management's current expectations for the fourth quarter, the Company now expects full year 2022 Adjusted OIBDA to be at the upper-end of the range of $370 - $385 million. This range of anticipated performance reflects a full live events touring schedule, including a large-scale international event, and increased monetization of third-party original programming, partially offset by increased costs to support the creation of content. The Company estimates fourth quarter 2022 Adjusted OIBDA of $83 - $90 million. The estimate reflects revenue growth primarily driven by an expected increase in media rights fees for the Company's premium live events as well as an expected increase in the monetization of third-party original programming. Similar to the prior year quarter, the fourth quarter 2022 estimate reflects expected revenue from the staging of a large-scale international event. The Company anticipates that fourth quarter results will also reflect the negative impact of the previously mentioned shift of revenue into the third quarter related to certain licensing agreements with minimum guarantees, as well as an increase in operating expenses, including certain costs to support the creation of content."

16:44 EDT Altice USA reiterates FY22 capex guidance - The company expects to continue to accelerate investments in key growth initiatives, reiterating cash capex guidance of approximately $1.7B-$1.8B in FY22.

16:43 EDT Chesapeake Utilities sees FY22 CapEx $140M-$175M - "During the nine months ended September 30, 2022, the Company experienced a reduced level of new capital investments due to regulatory delays and supply chain disruptions. As a result, the Company's capital expenditure guidance range for 2022 is projected to be $140 million to $175 million. The Company expects these impacts on its capital investment levels to be temporary and reiterates its long-term capital expenditures and EPS guidance ranges. These include capital expenditures in the range of $750 million to $1 billion from 2021 through 2025 and an EPS guidance range of $6.05 to $6.25 for 2025."

16:42 EDT Rubius Therapeutics evaluating sale of all or part of company, merger

16:41 EDT Rubius Therapeutics to reduce workforce by 84%

16:40 EDT Rubius Therapeutics: Dannielle Applehans to become president and CEO

16:39 EDT PDC Energy sees Q4 total production 245,000-255,000 Boe/d - For the fourth quarter, the company expects total production to be in a range of 245,000-255,000 Boe per day and 80,000-84,000 Bbls per day of oil production.

16:35 EDT Red Robin sees FY22 adjusted EBITDA $53M-$58M - The company states: "Due to higher commodity and operating costs, and strategic investments, the Company is updating its guidance as follows: Pricing in the mid-single digits; Mid-double digit commodity cost inflation; Mid-to-high single digit restaurant labor cost inflation; Selling, general and administrative costs of $138 to $142 million; Capital expenditures of $43 to $48 million; and Adjusted EBITDA of $53 to $58 million".

16:27 EDT Rogers confirms termination of merger pact with DuPont - Rogers Corporation (ROG) announced the termination of its definitive merger agreement with DuPont de Nemours (DD). In connection with the termination of the merger agreement, Rogers has received a regulatory termination fee of $162.5M from DuPont. As previously disclosed, the merger agreement provided both Rogers and DuPont with a right to terminate the merger agreement if the merger had not closed on or before November 1, 2022. Consummation of the merger was subject to various customary closing conditions, including regulatory approval by the State Administration for Market Regulation of China. As of November 1, 2022, the parties had not received regulatory approval from SAMR. Peter C. Wallace, Rogers' Board Chair, stated, "While we are disappointed with the outcome of this process, the strength of Rogers as a standalone business is undeniable. Our strategic plan provides a clear path towards future growth, and we look forward to expanding upon our leadership position and capitalizing on the many attractive opportunities ahead. We've always been focused on generating shareholder value and remain dedicated to this important objective on the journey ahead."

16:21 EDT MGM Resorts continues to pursue commercial gaming license in New York - MGM says it continues to pursue a commercial gaming license in New York and development of an Integrated Resort in Osaka, Japan.

16:18 EDT MGM Resorts continues to purshe commercial gaming license in New York - MGM says it continues to pursue a commercial gaming license in New York and development of an Integrated Resort in Osaka, Japan.

16:15 EDT Roku down 18% after Q4 guidance miss - Roku shares are down $9.63, or 18%, to $44.69 in after-hours trading.

16:14 EDT Waste Connections raises quarterly dividend 10.9% to 25.5c from 23c per share - To be paid on December 1 to shareholders of record on the close of business on November 16.

16:13 EDT Franklin Covey sees FY23 adjusted EBITDA $47M-$49M vs. $42.2M in FY22 - The company states: "Driven by the strength and strategic durability of its All Access Pass and Leader in Me membership subscriptions, which have driven accelerated growth over the past years, and continuing strong performance and momentum generated in fiscal 2022, the Company's guidance is that Adjusted EBITDA for fiscal 2023 will increase to between $47 million and $49 million in constant currency, compared with the $42.2 million in Adjusted EBITDA achieved in fiscal 2022. The Company expects to achieve this growth even after absorbing: 1) increased investments to add an estimated 40 new client partners in fiscal 2023, other personnel, and investments in the Company's delivery portals and content; 2) the potential for ongoing disruptions in China and Japan resulting from the COVID-19 pandemic and economic conditions in these countries; and 3) potentially challenging macroeconomic conditions. The Company's current outlook is that its Adjusted EBITDA will then increase to approximately $57 million in fiscal 2024, and to approximately $67 million in fiscal 2025. The Company remains confident in the strength of the All Access Pass and Leader in Me membership subscriptions, which have driven Franklin Covey's growth across recent years and which are expected to drive continued growth in fiscal 2023 and subsequent years."

16:09 EDT Barrett Business sees FY22 gross billings up 12%-13% - Sees FY22 effective tax rate 26%-28%.

16:07 EDT Allegiant Travel sees Q4 revenue up 26.5%-28.5% year-over-year, consensus $571M - Sees Q4 ASMs up 13.5% year-over-year.

16:06 EDT eBay reports Q3 GMV $17.7B - Down 11% on an as-reported basis and down 5% on an FX-Neutral basis.

16:05 EDT Qorvo announces $2B share repurchase program - Qorvo announced that its board of directors has authorized the repurchase of up to $2B of the company's outstanding common stock. The new repurchase program includes the remaining authorized dollar amount under the prior program which was terminated concurrent with the new authorization.

16:04 EDT ChromaDex sees high single digit revenue growth for FY, consensus $72.7M - Looking forward, for the full year, the Company expects high single digit revenue growth, driven by its global e-commerce business and growth with partners. For the full year, the Company expects approximately 60% gross margin, lower selling and marketing expense as a percentage of net sales, approximately $1 million increase in R&D, and approximately $6 to $8 million decrease in general and administrative expense, as reported, driven by lower legal expense. The Company expects to be cash flow break-even or better in the fourth quarter of 2022.

15:41 EDT A10 Networks raises dividend, announces new $50M buyback - Along with announcing financial results for its third quarter last night, A10 Networks announced that its board of directors approved a 20% increase in its quarterly cash dividend to 6c per share, payable on December 1 to stockholders of record at the close of business on November 15. Also, Dhrupad Trivedi, President and CEO of A10 Networks stated: "This performance enabled us to repurchase more than $47.5M of our stock, in both negotiated and open-market transactions, materially reducing our capitalization. Additionally, ongoing strength in our business positioned us to increase the quarterly dividend by 20% and authorize a new $50M stock repurchase plan. Simultaneously, we are strategically investing in technology, furthering our ability to capture market share and reinforcing our differentiators and driving durability for our business model despite macroeconomic conditions."

15:33 EDT BMO Financial increases U.S. dollar prime lending rate to 7% - BMO Financial announced that it is increasing its U.S. dollar prime lending rate from 6.25% to 7.00%, effective November 3.

14:43 EDT Senator Elizabeth Warren urges antitrust regulators to monitor Big Tech in autos - U.S. Senator Elizabeth Warren sent letters to Federal Trade Commision, FTC, Chair Lina Khan and Assistant Attorney General of the Antitrust Division at the United States Department of Justice, DOJ, Jonathan Kanter, calling for increased oversight of Big Tech expansion into the automotive industry. In the letter, the Senator highlights how the rapidly expanding role of Google (GOOG, GOOGL), Apple (AAPL), and Amazon (AMZN) in the auto industry raises competition concerns and urges the agencies to take swift action. "To achieve this dominance, Google, Apple, and Amazon are leveraging their market power in the mobile operating system, digital app markets, and data infrastructure spheres to become the dominant players in the automotive sphere. This expansion has potentially alarming implications for developers, workers, and consumers. I ask that you use your authority to address these concerns as they emerge and prevent further overreach by Big Tech companies," wrote Senator Warren. Big Tech firms have already begun embedding themselves into every aspect of future vehicles. At its Worldwide Developers Conference in June, Apple introduced the sweeping next generation of its car infotainment system CarPlay, promising to "reinvent the car experience" and claiming that CarPlay will no longer be just an infotainment system. Similarly, Google has announced several automotive partnerships, including a six-year partnership with Ford to integrate its Android Automotive Operating System into all new Ford (F) vehicles and to provide wide-ranging data, artificial intelligence, and machine learning services. Under this partnership, Google will play a role in everything from creating "digital experiences" for Ford customers to modernizing Ford's plant operations. Amazon is also establishing footholds for itself throughout the automotive industry, including creating autonomous driving systems, developing vehicle software, and investing in autonomous ground transportation." Reference Link

14:14 EDT Fifth Third to increase prime lending rate to 7% - Fifth Third Bank announced it will increase its prime lending rate to 7.00%, effective immediately. The rate was last changed on Sept. 21, 2022, when Fifth Third increased its prime lending rate from 5.50% to 6.25%.

14:04 EDT Bridgford Foods announces CFO Raymond Lancy to retire February 1 - Bridgford Foods announced that effective October 29, 2022, Raymond Lancy, Chief Financial Officer, Executive Vice President, Treasurer and Member of the Executive Committee will reduce his work schedule to 3 days a week. Lancy plans to fully retire on February 1. Cindy Matthews-Morales will be appointed Chief Financial Officer and member of the Executive Committee effective October 29. Mr. Lancy will become Vice President and Treasurer until February 1. The Company will execute a consulting agreement with Mr. Lancy in case there is a need for his services or for special projects. Mr. Lancy will remain on the Board of Directors for the upcoming term in 2023.

13:28 EDT North American rail traffic up 0.6% for the week ending October 29 - The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending October 29. Total U.S. weekly rail traffic was 514,457 carloads and intermodal units, up 0.8% compared with the same week last year.Total carloads for the week ending October 29 were 244,425 carloads, up 2.6% compared with the same week in 2021, while U.S. weekly intermodal volume was 270,032 containers and trailers, down 0.7% compared to 2021.Five of the 10 carload commodity groups posted an increase compared with the same week in 2021. They included coal, up 4,036 carloads, to 70,984; nonmetallic minerals, up 3,631 carloads, to 34,438; and motor vehicles and parts, up 2,365 carloads, to 15,002. Commodity groups that posted decreases compared with the same week in 2021 included chemicals, down 2,147 carloads, to 31,092; metallic ores and metals, down 1,916 carloads, to 22,108; and forest products, down 805 carloads, to 8,908. North American rail volume for the week ending October 29, on 12 reporting U.S., Canadian and Mexican railroads totaled 347,651 carloads, up 2.2% compared with the same week last year, and 355,130 intermodal units, down 0.9% compared with last year. Total combined weekly rail traffic in North America was 702,781 carloads and intermodal units, up 0.6%. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC), Union Pacific (UNP), FreightCar America (RAIL), Trinity Industries (TRN), Greenbrier (GBX) and Wabtec (WAB). Reference Link

13:10 EDT Boeing CEO says can hit mid-decade targets without China deliveries - Boeing CEO Dave Calhoun made the comment during the Q&A session of the company's investor day meeting.

12:34 EDT Boeing CEO says no longer targeting $50B annual sales for services - Boeing executives continue to present during the company's investor day meeting. Boeing shares are 2.7% higher in afternoon trading.

12:25 EDT Opendoor lays off 550 people across all functions, or 18% of staff - Opendoor Technologies CEO Eric Wu said in a letter to employees: "I mentioned that the best leaders lead with their head and their heart. It's with a heavy heart that I share this news today. For those who missed the Open House, we've made the difficult decision to reduce our team by ~550 people across all functions - approximately 18% of the company. The reality is, we're navigating one of the most challenging real estate markets in 40 years and need to adjust our business. To manage through the turbulence in the market, we've worked quickly over the last two quarters to reduce our operating expenses...Everyone leaving will receive ten weeks of pay, with an additional two weeks of pay for every full year beyond two years of tenure...We want to provide clarity on next steps as quickly as possible. We'll be sending an email to everyone at Opendoor within the next hour, which will let you know whether your role has been impacted or not." Reference Link

12:02 EDT Tupperware Brands falls -41.7% - Tupperware Brands is down -41.7%, or -$3.23 to $4.50.

12:02 EDT Chegg rises 23.2% - Chegg is up 23.2%, or $4.89 to $26.00.

12:01 EDT Hall of Fame Resort & Entertainment secures approval for sports betting licenses - Hall of Fame Resort & Entertainment Company announces it has taken the next step toward live sports betting by securing conditional approval from the state for mobile and retail sports books. The Ohio Casino Control Commission provided the required authorization for HOFV to gain licensing for a physical sports operation as well as an online betting platform, under Ohio's sports betting law HB29. Sports betting will become legal in Ohio on New Year's Day, 2023, when anyone in the state that is of legal betting age will be able to place wagers.

11:55 EDT Sony's PlayStation VR2 launches February 22, 2023 at $549.99 - Sony said that PlayStation VR2, a virtual reality headset compatible with the PlayStation 5 console, is officially launching on February 22, 2023. PlayStation VR2 Sense controller charging station, designed specifically for the PS VR2 Sense controller, will also launch the same day. The headset will have a recommended retail price of at $549.99/EUR599.99/GBP529.99/JPY74,980 and will come packaged with PS VR2 Sense controllers and stereo headphones. During this initial launch phase for our next-gen headset, players in the U.S., U.K., France, Germany, Belgium, Netherlands and Luxembourg will initially be able to pre-order PlayStation VR2 solely through PlayStation's online store at direct.playstation.com. Pre-orders will begin on November 15, and players may begin to register for pre-orders starting today. Orders from direct.playstation.com for PlayStation VR2 headsets and bundles will ship throughout the week of launch. In other markets, PlayStation VR2 will be sold at participating retailers, with pre-orders beginning on November 15. Information will be provided through participating local retailers in these regions. Reference Link

11:44 EDT Service Corp. raises quarterly dividend 8% to 27c per share - Service Corporation announced that its Board of Directors has approved an increase in its quarterly cash dividend to 27c per share of common stock. This quarterly cash dividend declared represents an 8% increase from the previously declared quarterly dividend of 25c per share of common stock per quarter.The quarterly cash dividend announced today is payable on December 30, 2022 to shareholders of record at the close of business on December 15, 2022.

11:27 EDT Dynatrace under pressure following Q2 beat, 2023 guidance cut - Shares of Dynatrace (DT) are under pressure on Wednesday after the company reported better-than-expected second quarter results but lowered its full year 2023 revenue outlook. QUARTERLY RESULTS: Dynatrace reported fiscal second quarter non-GAAP EPS of 22c and revenue of $279M, both better than the expected 18c and $272.48M, respectively. For the third quarter, the company said it sees revenue of $283M-$286M, with consensus at $285.42M. Dynatrace also lowered its guidance for the full year 2023 to $1.164B-$1.172B from $1.213B-$1.226B, with consensus at $1.13B. Additionally, the company announced the appointment of Jim Benson as CFO, effective November 15. ON THE SIDELINES: In addition this morning, Macquarie analyst Frederick Havemeyer initiated coverage of Dynatrace with a Neutral rating and $38 price target. The analyst is taking a cautious view on near-term macro headwinds. PRICE ACTION: In Wednesday morning trading, shares of Dynatrace have dropped almost 2% to $33.56.

11:22 EDT Boeing see $3B-$5B in free cash flow in 2023 - "Investment grade remains a priority for the company," Boeing executives said during the company's investor day meeting.

11:18 EDT Boeing sees about $10B in free cash flow, about $100B revenue in 2025/26 - 2025/2206 financial objectives shared during Boeing investor day meeting.

11:03 EDT Breach Inlet calls on Liberty Media board to spinoff Liberty Braves - Breach Inlet Capital delivered a letter to the Board of Directors of Liberty Media. It read in part, "Breach Inlet Capital, LP has been a patient and supportive shareholder of Liberty Braves (BATRK) for almost six years. Based on public disclosures, we are a top 25 shareholder with ownership of nearly 0.4mm shares. We have a history of constructively engaging public company boards to create value for shareholders. Consistent with this approach, we previously sought to privately express our views through a private letter we delivered to Liberty Media's Board of Directors in July 2022. However, one month passed before you even acknowledged our letter and another three months have passed without you taking any responsive action, as far as we can tell. Your lack of meaningful response over this extended period has led us to this point. Now, we send this second and public letter outlining our recommendations for value creation that we believe will benefit all shareholders. To summarize, we believe that i) BATRK's fair value is ~60% above its current share price and ii) this upside could be meaningfully captured by immediately spinning off BATRK from Liberty Media. Liberty Media owns BATRK, Liberty SiriusXM (LSXMK) and Liberty Formula One (FWONK). To enable investors to invest in the performance of each asset, LM created a tracking stock for each of these three assets in 2016. BATRK represents LM's ownership of the Atlanta Braves Major League Baseball team and The Battery, which is the real estate surrounding the Braves' stadium....Likely similar to most BATRK shareholders, we invested in BATRK because we believed: i) the Braves and the Battery were attractive and increasingly valuable assets, ii) recent MLB transactions implied BATRK was worth far more than its publicly-quoted trading price, and iii) the Board would take action to close the gap between BATRK's trading price and fair value by spinning off BATRK when tax-efficient. Based on public comments and disclosures, LSXMK and FWONK were both Active Trader Businesses as of February 2022.13 Therefore, LM should be able to tax-efficiently split its three tracking stock groups into standalone, asset-backed public companies. Or if LSXMK is not an ATB, then LM should still be able to tax-efficiently spinoff BATRK since FWONK is certainly an ATB. We believe either of these options would create substantial value for shareholders of BATRK, FWONK, and LSXMK and that the Board has a fiduciary duty to explore them. With Option 1: i) the complexity of LM's structure would be eliminated, ii) all tracking stocks would become asset-backed stocks, and iii) these could potentially then be tax-efficiently acquired. With Option 2: i) the complexity of LM's structure would be diminished with one less tracking stock ii) BATRK would be asset-backed, and iii) BATRK could potentially then be tax-efficiently acquired. Nine months have passed since FWONK became an ATB and the Board has still not publicly outlined a plan to separate these assets in order to maximize shareholder value. Therefore, we recommend the Board immediately announce Option 1 or Option 2 as described above. We are confident that either action would create significant value for all shareholders, which is the Board's primary fiduciary duty."

10:43 EDT NLS Pharmaceutics reports FDA grants orphan drug designation for Quilience - NLS Pharmaceutics announces that it has received Orphan Drug Designation, or "ODD," from the FDA in the United States for Mazindol, the active ingredient in its lead product candidate, Quilience, for the treatment of Idiopathic Hypersomnia, or "IH." "We are very pleased to receive ODD for Mazindol in the U.S. for the IH indication, given the potential versatility of this active ingredient in treating multiple sleep-wake disorders. In our recently reported Phase 2a top-line results, Quilience, our novel formulation and lead product candidate, demonstrated the ability to significantly promote wakefulness in narcolepsy patients with Type II disorder, which has strong similarities to IH. We are excited to advance our pipeline of Mazindol-based solutions, and the ODD status in addition to our formulation patents strengthen our ability to protect this franchise long-term as we seek to create significant shareholder value," said Alex Zwyer, CEO of NLS Pharmaceutics.

10:24 EDT East Stone Acquisition Corp trading resumes

10:08 EDT RS Group forms RS Safety Solutions brand - RS Group announced the launch of RS Safety Solutions as a new brand within the RS Group. RS Safety Solutions brings together the existing RS personal protection equipment capabilities with the operations of Needlers and Liscombe, both of which are based in the U.K. RS Group acquired Needlers and Liscombe in 2020 and 2021, respectively. Both businesses are leaders in their fields, with Needlers largely serving the food processing industry with its PPE and hygiene products and Liscombe primarily operating in industrial sectors, where safety and personal protection is critical. This union offers a deep technical experience and combines over 300 years of expertise in this field. The combination of the two businesses within RS Safety Solutions will enable the leveraging of their respective strengths to serve customers in industrial and food processing markets and address their requirements for PPE and safety and hygiene equipment. The unification also bolsters the huge potential for each of the forerunner operations and strengthens RS' position as a major player in the PPE market.

10:06 EDT InterPrice Technologies announces $7.3M Series A funding round - InterPrice Technologies announced the closing of its Series A funding. The $7.3M investment was co-led by Nasdaq Ventures and DRW Venture Capital, with participation from existing investors including Bowery Capital The company said, "InterPrice's solutions streamline bond, commercial paper, and loan pricing indications into intuitive dashboards across currencies and financing products. By normalizing data across all banking partners, the company's technology eliminates dependencies on time-consuming manual processes and enables corporate issuers to make informed financing decisions while expanding the reach of participating financing partners." With this additional funding, the company will accelerate product development, extend asset coverage, and expand its presence in the United States and internationally.

10:02 EDT Comcast, Charter announce Xumo as brand name for streaming JV - Charter Communications, Inc. (CHTR) and Comcast Corporation (CMCSA) announced their streaming platform joint venture will now operate and conduct business as Xumo, evolving the brand from a free ad-supported streaming TV service to an entire entertainment ecosystem inclusive of streaming devices, content, and a platform for partners to reach audiences at scale. Along with the naming of the joint venture, Charter and Comcast also announced that Flex, the 4K streaming device Comcast licensed to the joint venture will become Xumo Stream Box and XClass TV will become Xumo TV. Both devices will remain powered by Comcast's global technology platform and feature an entertainment experience designed to make it easy for consumers to find and enjoy their favorite streaming content through a world-class user interface and voice search. Xumo will go-to-market with its first branded devices in late 2023, distributed by Comcast, Charter and Walmart, with additional distributors to be announced in the future. Xumo's FAST service, which consists of hundreds of linear channels and on demand options from a growing collection of networks and content creators, will be rebranded Xumo Play. Xumo Play will anchor the free content offering on Xumo devices and continue to be available as an app on other streaming platforms.

10:00 EDT Tupperware Brands falls -41.7% - Tupperware Brands is down -41.7%, or -$3.22 to $4.51.

10:00 EDT Quad/Graphics rises 22.3% - Quad/Graphics is up 22.3%, or 60c to $3.29.

10:00 EDT Chegg rises 27.2% - Chegg is up 27.2%, or $5.73 to $26.84.

09:47 EDT Resideo falls -20.7% - Resideo is down -20.7%, or -$4.83 to $18.53.

09:47 EDT Rogers Corporation falls -44.0% - Rogers Corporation is down -44.0%, or -$101.01 to $128.48.

09:47 EDT Quad/Graphics rises 17.1% - Quad/Graphics is up 17.1%, or 46c to $3.15.

09:44 EDT Huadi International Group Co trading halted, volatility trading pause

09:40 EDT Semler Scientific Inc trading resumes

09:36 EDT Garrett Motion halts for volatility after rallying 4% to $7.75

09:35 EDT Semler Scientific Inc trading halted, volatility trading pause

09:34 EDT CN moves over 3.23M metric tons of grain in Ocober - The company said, "CN announced that October was the single best month ever for Western Canadian grain movement on CN's network. The Company moved over 3.23 million metric tonnes of grain from Western Canada. This exceeds the previous record set in October 2020 by over 50,000 metric tonnes and follows an all-time record set for weekly movement earlier in the month. These records were accomplished despite some challenges in the supply chain that CN and its supply chain partners addressed by working together."

09:32 EDT CMC Metals announces commencement of ESG initiative - CMC Metals announced the commencement of an initiative to develop Company policies and a manual relating to environmental, social and governance issues. John Bossio, Chairman notes, "This initiative is a great first step in addressing our collective will to ensure our corporate philosophy and operational plans serve to mitigate and adapt project impacts on the environment, climate change, local participation, indigenous concerns and participation, local communities, project benefits, employee safety and satisfaction."

09:24 EDT Terreno Realty acquires property in Los Angeles, CA for $17M - Terreno Realty acquired an industrial property located in Los Angeles, California on November 1 for a purchase price of approximately $17M. The property consists of one industrial transshipment building containing approximately 26,000 square feet on 1.8 acres. The property is at 5401 West 104th Street, west of I-405 and adjacent to Los Angeles International Airport, provides 19 dock-high loading positions and parking for 66 cars. The property is 100% leased to one tenant through September 2024. The estimated stabilized cap rate of the property is 2.5%.

09:19 EDT Helbiz and Italian insurtech firm YOLO launch in-app sales of digital insurance - Helbiz, and YOLO, Italy's first mover in insurtech are launching Helbiz Insurance, a new suite of digital insurance solutions for customers directly from the Helbiz app. Helbiz Insurance will start with the introduction of new digital insurance products as part of a broad collaboration agreement aimed at facilitating and protecting the lives of people on the move through an integrated ecosystem of services.

09:15 EDT Mace Security announces co-branding partnership with F3 Defense - Mace Security announced a co-branding partnership with F3 Defense. The agreement contemplates the offering of two new systems, the Mace Brand F3 Defense Passenger Protection System and the Mace Brand F3 Defense The Truck Stop Commercial Vehicle Protection System, which are designed for automobiles and trucks respectively and will be powered by Mace's MAG 9 12 oz pepper spray. The systems will be sold exclusively by Mace to the retail and automotive markets, firearms distributors, trucking associations and the trucking segment.

09:13 EDT Pitney Bowes and eBay announce cross-Border partnerships in US and UK - Pitney Bowes (PBI), a global shipping and mailing company that provides technology, logistics and financial services, announced that it will continue to provide a range of cross-border ecommerce logistics services to eBay (EBAY) in the US and UK. In the US, Pitney Bowes has been a partner to eBay since 2012 and will continue to support eBay's Global Shipping Program with leading technology, compliance and cross-border delivery services as eBay transitions Sellers from GSP to the new eBay International Shipping. Pitney Bowes will continue to be a partner, offering a range of ecommerce logistics services to support eBay International Shipping going forward. In the UK, Pitney Bowes has renewed its agreement to support eBay's UK Global Shipping Program as eBay looks to add Sellers to the program and drive more value to its successful and growing online marketplace. Pitney Bowes has provided technology, compliance and cross-border delivery services to help eBay Sellers in the UK reach consumers internationally since 2014. "As our partnership enters its second decade, Pitney Bowes is excited to be a part of eBay's renewed vision to make international selling as simple and seamless as domestic delivery for eBay Sellers and buyers around the globe," said Gregg Zegras, EVP & President, Global Ecommerce at Pitney Bowes.

09:10 EDT Gray Television promotes Finch to VP of News Services - Gray Television has promoted James Finch to Vice President, VP, of News Services. For the past several years, Finch has managed Gray's news vendor partnerships and assisted Gray's stations with content and resource sharing as Gray's Director of News Services. In his new role, Finch will continue his work and additionally lead Gray's new in-house news training program and our regional content producers.

09:09 EDT Marsh McLennan anounces acquisition of Bradley Insurance Agency, no terms - Marsh McLennan announced the acquisition of Bradley Insurance Agency, a commercial insurance broker based in Knoxville, Tennessee. Terms of the acquisition were not disclosed. Founded in 1972 by Steve Bradley, and acquired by Kendall and Kevin Bradley in 2014, Bradley Insurance serves organizations across multiple industries and sizes. All Bradley Insurance employees, including Kendall and Kevin Bradley, will be joining MMA. "With the addition of Bradley Insurance, we're expanding our insurance expertise in eastern Tennessee under the direction of a highly respected and accomplished team," commented Peter Krause, CEO of MMA's Southeast region. "We are proud to welcome Bradley Insurance to the MMA

09:09 EDT CareCloud provides RMIM with remote patient monitoring solution - CareCloud has partnered with Rocky Mountain Internal Medicine, RMIM, to apply the company's remote patient monitoring, RPM, solution to help RMIM proactively manage its patients' health conditions. RMIM signed on for CareCloud's remote patient monitoring solution, which CareCloud launched in September, to help their physicians provide even better care for patients who need it most. The talkEHR platform is built for interoperability and easy integration. "RMIM is committed to providing exceptional care to vulnerable patients," said Dr. Iram Fatima, CareCloud's chief operating officer for EHR and telehealth. "This echoes CareCloud's goal of offering valuable solutions that drive better health outcomes. Our partnership with RMIM has been mutually rewarding, as helping them implement better care for their patients reaffirms why CareCloud exists. We're here to offer solutions that enhance and strengthen healthcare for both providers and patients, and we're happy to see RMIM using our solutions to achieve this."

09:07 EDT Provectus announces WHO selection of RBS as INN for active ingredient - Provectus announced that the International Nonproprietary Names, INN, Expert Committee of the World Health Organization, WHO, has selected "rose bengal sodium," RBS, for the nonproprietary name of the Company's active pharmaceutical ingredient, API. Pharmaceutical-grade RBS is the API in Provectus' current clinical-stage drug product candidates and preclinical formulations. The RBS name was selected by the WHO Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations, reached the status of recommended INN after a period of public consultation, and was included in INN Recommended List 88 published with the No. 3 issue of the WHO Drug Information, Volume 36 in October 2022. Provectus is the first and only entity to have made pharmaceutical-grade RBS at a purity of nearly 100%. This success resulted from: The proprietary, patented, commercial-scale process to synthesize and utilize the RBS molecule as a viable drug substance for commercial use; The development of chemistry, manufacturing, and control specifications for drug substance and investigational drug product manufacturing processes; The production and multi-year stability testing of multiple drug substance and investigational drug product lots; The comprehensive documentation of lot composition and reproducibility; and The review and acceptance of CMC data from these lots by seven national drug regulatory authorities for a prior, global, multi-center, pivotal Phase 3 clinical trial. Dominic Rodrigues, Vice Chair of Provectus' Board of Directors, said "The World Health Organization's International Nonproprietary Names system has facilitated the name of rose bengal sodium for the active pharmaceutical ingredient that is the foundation of our clinical development and drug discovery programs comprising a number of different disease areas. We believe that finalizing this name is an important step towards enabling drug regulatory agencies to ensure strong pharmacovigilance of rose bengal sodium in medicines."

09:04 EDT Bonaccord Capital Partners announces minority investment in VMG Partners - Bonaccord Capital Partners, a part of P10, announced that it has acquired a passive minority equity interest in VMG Partners, a private equity firm focused on partnering with entrepreneurs and managers to support the growth and strategic development of leading branded consumer product and technology companies through its Growth and Catalyst funds. Bonaccord's investment provides an opportunity for VMG to source additional capital to further support its products and to invest on behalf of its employees. Bonaccord will serve as a strategic partner to VMG, and the investment will have no impact on the day-to-day management or operations of the firm.

09:03 EDT Fortinet announces FortiGate 1000F series of next-generation firewalls - Fortinet announced FortiGate 1000F, the latest series of next-generation firewalls from Fortinet to deliver higher performance-more than seven times faster firewall throughput-and lower power consumption-83 percent fewer watts per Gbps of firewall throughput-than competitive solutions.

09:02 EDT Alaska Air announces new partnership with Lyft - "Alaska Airlines (ALK) has hitched a new partnership with Lyft (LYFT) one of the largest transportation networks in the U.S. and Canada - and we're eager for our guests to come along for the ride. Starting today, our Mileage Plan members can earn miles for their everyday Lyft rides - such as trips to and from the airport, heading out to a concert or across town for a holiday party. The sky's the limit. All it takes is a simple step of linking your Mileage Plan and Lyft accounts. And we're adding a festive bonus. Between now and Dec. 31, 2022, our members will earn double miles: two miles for every dollar* spent on rides everywhere Lyft operates in the U.S. and Canada."

09:01 EDT Ford announces three senior leaders plan to retire - Three Ford Motor Company senior leaders - Joy Falotico, Stuart Rowley, and Steven Armstrong - have announced plans to retire after serving in roles during careers that span more than three decades at Ford. With these changes, Jim Baumbick, vice president, product development operations, cycle planning and internal combustion engine programs, will take on responsibility for delivering industry-leading quality at Ford. Josh Halliburton, executive director of quality, will now report to Baumbick. Stuart Rowley, Ford's chief transformation and quality officer, plans to retire Dec. 1 after more than 32 years with Ford. Joy Falotico, president of Lincoln since 2018, is retiring Dec. 1 after helping to drive the resurgence of Ford's storied luxury brand. Under Falotico's leadership, Lincoln refined its Quiet Flight brand DNA manifested by elegant design, a smooth, quiet driving experience, and a sanctuary-like experience inside the vehicles. Falotico will be succeeded by Dianne Craig. Steven Armstrong, vice president, India and South America Transformation, will retire Jan. 1, 2023, after 35 years with Ford. He has held many senior management and purchasing positions for Ford-owned Jaguar and Volvo in addition to Ford of Europe.

08:58 EDT CVS Health expects FY23 cash flow 'similar' to FY22 - Says "continuing to perform on strategy."

08:55 EDT Gaucho Group's Algodon Wine Estates receives approval to drill water well - Gaucho Group Holdings announced that its subsidiary Algodon Wine Estates has received approval from the Mendoza's Departamento General de Irrigacion to drill its third water well to service the estate's 4,138 acre wine, wellness, culinary and sport resort and luxury residential development, in San Rafael, Mendoza, Argentina. This follows previously announced news of approval to create the estate's first and second water wells which have since been drilled. The Company believes this continued initiative can significantly enhance the property's valuation, as it further primes the real estate project for expansion. Algodon Wine Estates anticipates applying to the local municipality to drill for additional water wells with a goal of a total of 6 throughout the property. The successful completion of this initiative is intended to allow access to natural aquifers that can service the expansion of the estate's real estate project, vineyards and winery, and other amenities. Algodon Wine Estates' luxury residential development is comprised of over 400 estate lots in its Phase 1 plan and also features the vineyards and winery responsible for producing the wines of Algodon Fine Wines, as well as a boutique hotel, with amenities such as a nine-hole golf course, grand slam style tennis courts, a year-round restaurant serving traditional Argentine cuisine, and other services. More than 100 vineyard lots overlook the golf course, and the wines cultivated at the estate have garnered multiple awards from international tasting competitions. The Company is also continuing to build out the infrastructure of its revised masterplan for an ultra-luxury 60-room hotel and spa, that is also slated to include 30-50 residences, for which Algodon Wine Estates seeks to co-brand with a luxury hotel brand. The revenue potential from the hotel rooms and branded residences could generate an additional $25 million per year. The masterplan further builds upon the estate's award-winning vineyard development by emphasizing the existing winery and 1946 vines, the local Mendocino culture, as well as the estate's existing terrain, amenities, and features. The masterplan includes development of an additional 200 lots, ranging in size from 2.47 acres to 6 acres. The Company anticipates sales of these additional lots could ultimately generate more than $100 million in revenues.

08:54 EDT Forza X1 receives 50 electric boat reservations in last 90 days - Forza X1 announced that since the end of July 2022, the Company has received 50 non-binding pre-production reservations for its initial two models, the FX1 Dual Console and FX1 Center Console which, if ultimately finalized, could result in more than $8.5 million in revenue for the Company following delivery. With a reservation price of $100, customers can personalize their FX1 Dual or Center Console directly through Forza X1's website by specifying hull color, battery capacity, and upholstery color. The Company will continue to accept reservations for its FX1 until its ready to commence formal sales. Reservations are non-binding and cancellable before manufacturing.

08:52 EDT Rubicon and Walmart team to continue waste diversion, consolidate services - Rubicon Technologies (RBT) announced that it has signed a two-year agreement with Walmart (WMT), to continue to increase the multinational retail corporation's waste diversion from landfills, consolidate services, and provide enhanced account management for distribution centers and retail stores. Walmart understands that for a business to last, it must have a fundamental reason for being, which is found in the value it creates not only for shareholders, but for the world. Rubicon's mission is to end waste. By collaborating with Rubicon and others, Walmart continues on a path to becoming a regenerative company, one dedicated to placing nature and humanity at the center of its business practices.

08:51 EDT Global Industrial opens distribution center in Toronto - Global Industrial Company announced the opening of its new distribution center in Toronto, Canada, which has commenced full operations, including outbound shipments to customers. The state-of-the-art distribution center, which replaces a smaller facility in the Toronto area, is designed to allow Global Industrial to increase service levels to customers in Canada and significantly shorten delivery times. With the new facility, Global Industrial expands its distribution center footprint and inventory capacity in Canada by more than three times, increases fulfillment autonomy in the region and provides additional capacity to support future growth.

08:47 EDT Mobile Global Esports appoints Kim Meltzer as managing director - Mobile Global Esports announced that noted esports event producer Kim Meltzer has joined the Company as managing director. For over ten years, Kim has focused her career exclusively on global esports events supporting brands, the community, production, publishers, developers, high school, college and professional players, as well as influencers. Meltzer is the Co-Founder and Chief Executive Officer of Destination Esports, a women-owned and led full-service experiential esports creative group.

08:46 EDT SOBR Safe enters oil and gas industry via multi-site SOBRcheck demonstrations - SOBR Safe announced that its entering the oil and gas industry through multi-site SOBRcheck demonstrations, as sponsored by TerraTech - one of the world's largest oilfield services and logistics providers. Oil and gas experiences the highest rate of binge drinking of any industry in the United States: Across all industries and occupations, binge drinking is most common among oil and gas extraction workers at 26%; Four other safety-sensitive occupations critical to oil and gas rank in the first five positions for excessive drinking, including construction; installation, maintenance & repair; production; and transportation; Per the 2021 US Census, these oil and gas occupations employ more than 50,000 workers' Across all occupations, the industry employs over 100,000 people.

08:44 EDT Tortoise announces preliminary results of tender offers - Tortoise announced the preliminary results of cash tender offers for each of the following Funds that expired at 5:00 P.M., Eastern Time on November 1, 2022. TYG: Up to 5% or 596,395 of its outstanding common shares; Shares properly tendered 5,100,300; purchase price $38.96; NTG: Up to 5% or 282,149 of its outstanding common shares; 2,668,170; $43.88; TTP: Up to 5% or 111,388 of its outstanding common shares; 1,033,782; $32.9; NDP: Up to 5% or 92,299 of its outstanding common shares; 1,017,134; $38.72; TPZ: Up to 5% or 326,324 of its outstanding common shares; 3,126,360; $15.24.

08:39 EDT LiveRamp, Meta Platforms expand partnership to power 'seamless' optimization - LiveRamp (RAMP) announced an expanded partnership with Meta (META), enabling marketers to privately and securely use their first-party data to target, measure, and optimize campaigns to drive greater returns from their marketing investments - all powered by LiveRamp's people-based, privacy-first identifier, RampID. LiveRamp's Authenticated Traffic Solution is now available for marketers to connect to Facebook's Conversions API. Using RampID, the integration optimizes campaign performance while protecting consumer data, ensuring brands can build marketing programs upon a durable foundation using technology designed to withstand evolving privacy and browser policies.

08:38 EDT CVS Health says ability to generate cash 'remains strong' - Says liquidity, cash position "remain excellent." Sees higher levels of investment spending in Q4. Expects to repurchase shares in 2023 "opportunistically."

08:37 EDT Natera awarded contract with the U.S. Department of Veterans Affairs - Natera announced that it was awarded a nationwide contract, effective Sept. 15 with the U.S. Department of Veterans Affairs, or VA, National Precision Oncology Program, to provide minimal residual disease, or MRD, and monitoring services with the company's personalized and tumor-informed MRD test, Signatera. The VA is the largest integrated health system in the country, providing care to over 450,000 veterans living with cancer.1 Through this contract the Signatera test will be made available for serial use, to help detect residual disease and inform difficult treatment decisions. Signatera is covered by Medicare for use in colorectal cancer, muscle invasive bladder cancer, and pan-cancer immunotherapy monitoring, and has been validated across multiple cancer types to detect recurrence earlier than standard diagnostic tools2,3 and to help assess treatment response in conjunction with imaging.

08:36 EDT NextNav acquires Nestwave SAS - NextNav announced that it acquired Nestwave SAS, a privately held global leader in low-power geolocation, for an enterprise value of $18.0M with a gross consideration value of $19.3M, consisting of $4.3 million in cash and $15.0M in NextNav common stock. The transaction closed on October 31. Based in Neuilly-sur-Seine, France, Nestwave provides advanced geolocation solutions to Internet of Thing, or IoT, modem and digital signal processor vendors and end IoT users. The combination of NextNav's technology with Nestwave's LTE/5G capabilities will allow NextNav to intelligently combine signals from existing terrestrial LTE/5G networks with its own highly synchronized TerraPoiNT system to deliver near nationwide resilient 3D position, navigation and timing capabilities which will contribute to dramatically lower deployment costs. The Company expects to reduce its deployment costs by approximately 75% or in excess of $250M, along with a commensurate reduction in associated network OpEx costs, enabling it to serve the crucial markets of timing for critical infrastructure, aviation, automotive, IOT and other mass market applications sooner.

08:35 EDT iRhythm comments on announcement of MPFS Final Rule for calendar year 2023 - iRhythm Technologies commented on the recent announcement from the Centers for Medicare and Medicaid Services that it has issued the Medicare Physician Fee Schedule, MPFS, Final Rule for Calendar Year 2023. On November 1, 2022, CMS stated in its fact sheet that the Final Rule includes payment policies, payment rates and other provisions for services furnished on or after January 1, 2023. In the advanced copy of the Final Rule linked in the CMS Fact Sheet, CMS commented that the Final Rule will include national pricing for Current Procedural Terminology codes 93241, 93243, 93245, and 93247 along with an updated price of $260.35 for the extended external ECG patch, medical magnetic tape recorder, SD339, supply item. The SD339 supply item price of $260.35 in the Final Rule is a positive improvement from the $245.69 price that CMS included in their Proposed Rule issued in July 2022. iRhythm is waiting for the Final Rule and accompanying addenda to be published on the Federal Register before providing further comments on the national pricing for CPT codes 93241, 93243, 93245, and 93247 and its potential impact to its business.

08:32 EDT ABVC BioPharma announces CSMC joins Phase I study of ABV-1601 - ABVC Biopharma announced that the Cedars-Sinai Medical Center, CSMC, Institutional Review Board, IRB, has approved their institution joining the Phase I study of ABV-1601 for treating depression in cancer patients. The Principal Investigator of the CSMC study will be Dr. Scott A. Irwin, MD, PhD., an eminent Professor of Psychiatry & Behavioral Neurosciences. The Phase I study is open label and will be conducted with 12 cancer patients with moderate to severe depressive symptoms. The main objective of the study is to evaluate the safety of PDC-1421, the primary active ingredient in ABV-1601. The second objective is to determine the most effective dosages for a randomized, double-blind, non-inferiority Phase II trial of PDC-1421 that ABVC expects to initiate in 2023. "We are delighted to receive IRB approval from Cedars-Sinai Medical Center, a prestigious hospital in the United States, for the Phase I study of ABV-1601 for depression in cancer patients," said Dr. Howard Doong, ABVC BioPharma's chief executive officer. "We can now schedule the site initiation visit in November or December of this year."

08:29 EDT Biomerica InFoods IBS data presented at 2022 American College of ACG - Biomerica announced that data derived from a clinical study of InFoods IBS was presented at the 2022 American College of Gastroenterology, ACG, Annual Scientific Meeting in a poster titled "IgG-based Elimination Diets for Patients with IBS: Results From a Prospective, Multi-Center, Double-Blind, Placebo-Controlled Trial." The poster was selected by ACG as a "Presidential Poster." Fewer than 5% of accepted ACG abstracts each year receive this distinction, which is awarded for high quality, novel and potentially industry disruptive research. The outcomes of this prospective, multi-center, double-blinded, placebo-controlled clinical trial presented at ACG showed that IBS patients who used the InFoods IBS test to guide the elimination of specific foods from their diets for eight weeks led to a material improvement of symptoms over placebo in several IBS measures including: abdominal pain intensity, bloating, Subject Global Assessment of Relief and the Global Improvement Scale. People with IBS-Constipation and IBS-Mixed who participated in the study showed the greatest decrease in symptoms. No significant adverse events were reported. In the data presented at the ACG annual meeting, for the Abdominal Pain Intensity responder endpoint of greater than30% improvement in pain, patients with IBS Constipation and IBS Mixed in the treatment diet arm had a statistically significant improvement over patients in the placebo diet arm. The improvement for patients in the treatment versus the placebo is considered clinically significant and is similar and, in some cases, better than the current drugs in the market.

08:27 EDT Turquoise Hill acknowledges announcement made by Rio Tinto - Turquoise Hill (TRQ) acknowledged the announcement by Rio Tinto (RIO) of agreements entered into between Rio Tinto, Rio Tinto plc and certain shareholders of the company related to Pentwater Capital Management LP and SailingStone Capital Partners holding in aggregate 32,617,578 common shares of the company. The agreements contain terms whereby the parties agreed that the named shareholders would withhold their votes relating to the arrangement. The agreements were entered into in relation to the proposed statutory plan of arrangement pursuant to which, subject to the satisfaction or waiver of all applicable conditions precedent, Rio Tinto will acquire the approximately 49% of the issued and outstanding common shares of Turquoise Hill that Rio Tinto and its affiliates do not currently own for C$43.00 per share in cash. Each of the named shareholders have exercised or will exercise dissent rights in connection with the arrangement. Turquoise Hill is not party to the agreements and neither it nor the special committee of its independent directors was involved in the negotiation of the agreements. Pursuant to the terms of the agreements, the parties agreed, among other things, that: the named shareholders will withhold their votes in respect of the special resolution of shareholders of the company to approve the arrangement; proceedings in respect of the named shareholders' dissent rights in connection with the arrangement, as well as certain oppression claims against Rio Tinto and its affiliates, will be conducted in accordance with procedures set out in the agreements, which include mediation to be completed within 60 days of closing of the arrangement and, absent resolution at mediation, confidential binding arbitration which the parties agree to use reasonable commercial efforts to complete within 12 months of the conclusion of the mediation; the named shareholders will receive 80% of the consideration within two business days of closing of the arrangement and 20% of the consideration, plus interest thereon, upon final determination of the dissent procedures set out in the agreements; the agreements also provide for the mediation and, if necessary, arbitration of the fair value amount remaining to be paid, if any, by Rio Tinto to the named shareholders to resolve the dissent proceedings and the damages or compensation amount, if any, to be paid by Rio Tinto to the named shareholders to resolve the oppression claims; Rio Tinto will waive the closing condition in the arrangement agreement relating to the exercise of dissent rights to allow the arrangement to be completed in circumstances where holders of up to 17.5% of the common shares of the company validly exercise dissent rights; and the named shareholders also provided covenants related to non-disparagement, non-interference and a release of all claims against Rio Tinto plc, Rio Tinto, the company and their respective affiliates and past, present or future directors, officers or employees other than obligations under the agreements, claims related to the dissent proceedings and Oppression Claims and claims related to the U.S. securities law class action proceeding against Rio Tinto in the Southern District of New York. The special committee was first advised of the potential terms of the agreements on the evening of Sunday, October 30. The special committee suggested to Rio Tinto that it offer comparable dissent proceedings as those offered to the named shareholders in the agreements to all holders of minority shares. Rio Tinto advised that it was not making the terms of the agreements available to all minority shareholders. Minority Shareholders other than the named shareholders who properly exercise their dissent rights will continue to be entitled to the dissent proceedings provided for under Section 193 of the Business Corporations Act, as modified by the interim order of the Supreme Court of Yukon dated September 29 and the plan of arrangement pertaining to the arrangement. The Special Committee recognizes that as a result of Rio Tinto's entry into the agreements minority shareholders may require additional time to consider this new information. Accordingly, the special committee requested, and Rio Tinto agreed, that the special meeting originally scheduled for November 1 be postponed to provide minority shareholders sufficient time to consider this new information.

08:25 EDT Iris Energy announce update on financing arrangements - Iris Energy announced an update on its financing arrangements as well as a recent opportunity to utilize prepayments made to Bitmain Technologies. Highlights: The Group has limited recourse equipment financing arrangements in wholly-owned special purpose vehicles, which have no parent company guarantee or recourse to any other Group entities; The Group has $53 million of cash in the bank as at October 31, 2022; These financing arrangements were intentionally structured for prudent risk management to protect the underlying business and data center infrastructure the Group has built; Certain equipment owned by the special purpose vehicles currently produce insufficient cash flow to service their respective debt financing obligations, and have a current market value well below the principal amount of the relevant loans; 2.4 EH/s of miners2 and all of the Group's data center capacity & development pipeline are unaffected by these financing arrangement; The Group is exploring opportunities to utilize data center capacity that may become available, recognizing: Current scarcity of industry hosting data center capacity and Prospect of utilizing $75 million of prepayments already made to Bitmain in respect of an additional 7.5 EH/s of contracted miners for further self-mining

08:23 EDT FactSet announces the launch of FactSet Model Center - FactSet announced the launch of FactSet Model Center, a no-cost marketplace for wealth advisors to access the industry's investment solutions within a single, integrated platform. FactSet Model Center provides advisors with pre-built model portfolios from leading asset managers, product metadata, and detailed marketing materials, including factsheets in an easy-to-navigate system. "Investors continue to demand more transparency and portfolio management, thereby putting pressure on advisors to continue expanding their offering while improving internal efficiencies," said Goran Skoko, EVP, Head of Research and Advisory Solutions at FactSet "Through the launch of FactSet Model Center, advisors can access pre-built model portfolios from leading asset managers as well as the industry's best in class investment solutions in a single platform, allowing them to spend more time on business development and client services."

08:22 EDT Oyster Point Pharma reports inducement grants under Nasdaq listing rule - Oyster Point Pharma announced that the Compensation Committee of the Company's Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 14,400 shares of common stock to seven new employees, pursuant to the Oyster Point Pharma, Inc., 2021 Inducement Incentive Plan. Each stock option has an exercise price equal to $8.08 per share, Oyster Point Pharma's closing trading price on the grant date, and will vest over four years, with 1/4th of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/36th of the remaining underlying shares vesting on each monthly anniversary thereafter, subject to the new employees' continued service relationship with Oyster Point Pharma through the applicable vesting dates.

08:21 EDT Grom Social subsidiary teams up with Radix to offer Radix TeacherView - Grom Social Enterprises announced that its subsidiary Grom Educational Services has teamed up with tech management company, Radix, to offer Radix TeacherView, a cloud-based management education solution that will be offered to schools and districts alongside Grom's NetSpective web filtering solution. The collaboration of the two companies was announced jointly today by Darren Marks, Chairman & CEO, Grom Social Enterprises, Inc and Michael Shoham, CEO of Radix. Grom Educational will immediately begin to offer Radix TeacherView along with its NetSpective web filtering solution, a product schools rely upon to protect students from harmful internet content.

08:20 EDT Actinium Pharmaceuticals appoints Caroline Yarbrough as Chief Commercial Office - Actinium Pharmaceuticals (ATNM) announced the appointment of Caroline Yarbrough as Chief Commercial Officer. Caroline joins Actinium from Novartis (NVS) where she most recently served as Portfolio General Manager, US Oncology, with full P&L responsibility of a diverse portfolio of brands and development assets with revenues in excess of a billion dollars. Previously, she led the chronic myelogenous leukemia portfolio, a billion-dollar business comprising TASIGNA and SCEMBLIX. She also led strategic account management during the launch period for KYMRIAH, the first approved CAR-T cell therapy. Prior to Novartis, Caroline's career spanned multiple large pharmaceutical and biotechnology companies, including Glaxo SmithKline (GSK), Bristol Myers Squibb, ViroPharma and Merck (MRK), where she held roles with increasing responsibilities.

08:18 EDT Jounce earns clinical milestone payment under agreement with Gilead - Jounce Therapeutics (JNCE) announced earning a $15M clinical milestone payment from Gilead Sciences (GILD) under the exclusive license agreement for GS-1811, an anti-CCR8 antibody for which Gilead has exclusive rights to develop and commercialize. GS-1811 is designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory, TITR, cells in the tumor microenvironment. Under the terms of the September 2020 agreement, Gilead invested $35M in Jounce's common stock and made an $85.0 million upfront payment to Jounce. Jounce led the development of JTX-1811 through IND clearance, after which Gilead obtained the sole right to develop and commercialize the program. After receiving this $15M milestone payment, Jounce may receive up to an additional $645M in future clinical, regulatory and commercial milestone payments and will also be eligible to receive royalties ranging from high single digit to mid-teens based upon worldwide sales. Any milestone or royalty paid to Jounce is subject to certain reductions as described in the license agreement.

08:16 EDT Surge Copper completes assay results for 7 holes from its Oosta Property - Surge Copper announces complete assay results for 7 holes from the Company's 100% owned Ootsa Property in British Columbia. Included are results from 3 holes testing exploration targets and 4 holes from the eastern extension of the Seel Breccia Zone where the Company identified potential to expand high-grade breccia-style mineralization within an area of increasing glacial cover. These are initial results from the first of a two-phase, $6.5 million program which was designed to advance numerous early-stage regional exploration targets within the 50-kilometre Berg-Huckleberry-Ootsa porphyry copper belt through surface reconnaissance exploration and target drill testing.

08:15 EDT Mainz Biomed provides third quarter 2022 update - Mainz Biomed provided an update on accomplishments during the third quarter which ended September 30, 2022. Key Highlights and Recent Developments: Expanded European and international commercial franchise for ColoAlert; Maintained execution timeline for ColoFuture; Continued final preparations for U.S. pivotal clinical study evaluating next-generation CRC test - on track to commence in Q4 2022; Formed a Medical Advisory Board; Bolstered leadership team by appointing two executives to the Board of Directors. "The major emphasis for the past quarter was to continue executing our commercial strategy for ColoAlert across Europe and in select international territories while making final preparations to launch our U.S. pivotal clinical study designed to evaluate a next-generation self-administered diagnostic test for CRC," commented Guido Baechler, Chief Executive Officer of Mainz Biomed. "We head into the final months of 2022 with great momentum across corporate and product development fronts, and I look forward to keeping our shareholders and interested parties posted on progress." Commercial Update - During the quarter, Mainz Biomed launched ColoAlert's consumer commercial program in Italy and the United Arab Emirates through its partnership with Dante Labs, a global leader in genomics and precision medicine. Dante is now marketing ColoAlert through its extensive database and selling via Dante's region-specific eCommerce websites. Under the terms of the partnership, samples are initially being processed at Mainz Biomed's in-house facility. Product Development Update: Advancing ColoFuture & preparing for U.S pivotal clinical trial - Throughout the third quarter, Mainz Biomed continued enrolling patients in ColoFuture, its international multi-center study assessing the potential to integrate a portfolio of novel gene expression biomarkers into ColoAlert. The study remains on target to report results in the first half of 2023. In the U.S., the Company continued preparing to initiate its pivotal clinical study of a next-generation CRC diagnostic test. Mainz Biomed is on track to initiate the trial in Q4 2022 and anticipates reporting results in 2025.

08:13 EDT Calavo Growers moves to quarterly dividend of 28.75c per share - Calavo Growers announced that it will begin declaring and paying dividends on a quarterly basis rather than annually as has been its practice. Calavo's Board of Directors declared a quarterly dividend of $0.2875 payable on December 14, 2022 for shareholders of record as of the close of business on November 16, 2022.

08:12 EDT Regulus doses first patient in Phase 1b MAD study of RGSL8429 - Regulus Therapeutics announced the dosing of the first patient in the Phase 1b MAD study of RGSL8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease, or ADPKD. The Phase 1b MAD study is a double-blind, placebo-controlled trial to assess safety, tolerability, and pharmacokinetics of RGLS8429 in adult patients with ADPKD. The study will evaluate the safety and efficacy of RGLS8429 treatment across three different dose levels including measuring changes in polycystins, cystic kidney volume (htTKV), and overall kidney function. The first cohort will be dosed at 1 mg/kg of RGLS8429 or placebo every other week for three months. Topline data from the first cohort of patients is expected in mid-2023.

08:11 EDT NV5 Global announces it acquired Intrepid Engineering - NV5 Global announced that it has acquired Intrepid Engineering, a provider of mechanical, electrical, and plumbing, MEP, systems design for facility renovations and new construction. The acquisition was made with a combination of cash and stock and will be immediately accretive to NV5's earnings. "Intrepid diversifies our MEP practice in Las Vegas beyond the hospitality industry and introduces us to clients in industries such as healthcare and education who can benefit from NV5's service portfolio," said Dickerson Wright, PE, Chairman & CEO of NV5. "Intrepid's principals are board certified licensed professional engineers in mechanical and electrical engineering and will enhance our technical resources in this high-growth geographical area."

08:10 EDT Genasys awarded 5-year contract by California County for its GEM services - Genasys announced that San Diego County, California has entered into a five-year contract with the Company for Genasys Emergency Management, GEM, software services. GEM is replacing San Diego County's previous regional notification system. "This is the second county in Southern California to select GEM for emergency management and critical notification services," said Richard Danforth, Chief Executive Officer, Genasys Inc. "Between San Diego County and the previously announced Riverside County contract, GEM will cover more than 5.8 million residents, 2 million housing units, and 130,000 businesses." Danforth added, "With this award, emergency management agencies, first responders, and more than 15 million Californians statewide will have access to Genasys' unified critical communications solutions to help prepare for and protect against wildfires, flooding, debris flows, tsunamis, earthquakes, and other life safety hazards. Additional Genasys software and hardware systems contracts from California jurisdictions are expected this year."

08:09 EDT Western Union enters renewed five-year agreement with Walgreens - Western Union (WU) and Walgreens (WBA) announced a renewed five-year agreement to their long-standing relationship. As a result, consumers will continue to have access to Western Union Money Transfer and bill payment services at nearly 9,000 Walgreens locations across the United States.

08:09 EDT Mullen Automotive eliminates approximately $13M in debt - Mullen Automotive announces that it has eliminated $13M in company debt and has reduced its overall indebtedness from more than $30M last year to a current estimate of less than $10M. Mullen continues to strengthen its financial balance sheet with the recent elimination of approximately $13M in company debt, which was associated with a debt obligation to Esousa Holdings, LLC. It is anticipated that this debt conversion will save the Company more than $3.5M in interest expenses. Mullen continues to maintain its good financial health, with now less than an estimated $10M approximately left of outstanding indebtedness. This elimination of and reduction in debt is significant, considering the overall debt balance at the end of 2021 was over $30M.

08:08 EDT Roper Technologies partners with DAT to launch capacity-based pricing tool - Parade announced an exclusive partnership with DAT Freight & Analytics to power Parade's capacity-based pricing tool called Advantage. The collaboration combines DAT's new, best-in-class dynamic predictive benchmark with powerful data on a broker's carrier relationships and lane expertise from Parade's capacity management platform. "Our expanded collaboration with DAT brings our customers powerful dynamic pricing based on real carrier relationships coupled with the industry-leading freight rate benchmark and forecasts," said Anthony Sutardja, CEO of Parade. "The seamless integration opens the door to enabling every freight broker to win more business, more profitably." Freight brokers using Parade can price loads simply by inputting a lane and any special load features or accessorials. They will see DAT's real-time prediction of current and future market rates alongside historical trends with DAT RateView.

08:07 EDT Ardmore Shipping approves initiation of a quarterly cash dividend - Ardmore Shipping announced today that its Board of Directors has approved the initiation of a quarterly cash dividend as a component of the Company's longstanding Capital Allocation Policy. Commencing with the Company's performance for the quarter ending December 31, Ardmore intends to pay a quarterly cash dividend equivalent to one-third of Adjusted Earnings for the applicable quarter. The declaration and payment of dividends is subject to the discretion of our Board of Directors.

08:06 EDT United Airlines launches Calibrate program to develop AMT pipeline - United Airlines announced the launch of Calibrate, an in-house apprenticeship program that will help grow and diversify its pipeline of Aircraft Maintenance Technicians. The inaugural class starts next week in Houston as the airline plans to train more than 1,000 people at about a dozen locations by 2026, with the goal of at least half being women or people of color. Calibrate is a 36-month program in which participants "earn and learn" getting paid while completing the full-time certification and training process. Since participants get paid while they train, they forgo the expense of going to a technical school - which can cost up to $50,000. United will start accepting external applications in early 2023.

08:05 EDT Bath & Body Works appoints Boswell as Chief Executive Officer - Bath & Body Works (BBWI) announced that the Company's Board of Directors has voted unanimously to appoint Gina Boswell Chief Executive Officer and a member of the Board, effective December 1, 2022. Sarah Nash, who has served as Executive Chair of the Board since February 2022 and interim Chief Executive Officer since May 2022, will remain Executive Chair through the end of the Company's fiscal year on January 28, 2023, at which time she will transition back to Chair of the Board. Boswell has more than 30 years of experience, including extensive beauty and personal care leadership roles at global companies such as Unilever (UL).

08:03 EDT Morphic expects cash equivalents to fund operations through second half of 2025 - As of September 30, 2022, Morphic had cash, cash equivalents and marketable securities of $371.8 million, compared to $397.6 million as of June 30, 2022. Morphic believes its cash, cash equivalents and marketable securities as of September 30, 2022, will be sufficient to fund operating expenses and capital expenditure requirements into the second half of 2025.

07:53 EDT Clean Harbors appoints COO Eric Gerstenberg, CFO Michael Battles as co-CEOs - Clean Harbors announced that it has appointed COO Eric Gerstenberg and CFO Michael Battles as co-CEOs of the company, effective March 31, 2023. As part of a long-planned transition, they will be succeeding Clean Harbors' founder Alan McKim, who has been CEO for the past 42 years. McKim will become executive chairman of the board of directors and CTO where he will continue to spearhead the company's M&A and technology initiatives. Battles and Gerstenberg will work together as co-CEOs to jointly direct the day-to-day operations and continued growth of the company. Gerstenberg joined Clean Harbors in 1989 and during the past thirty years he has held a variety of positions of increasing responsibility throughout the organization. He was most recently COO, a position he has held since 2015, where he had responsibility for the company's environmental sales & service organization, all of its facilities including incinerators and re-refineries, and oversaw the majority of its workforce.

07:50 EDT FDA approves Gilead sNDA for Vemlidy to treat pediatric hepatitis B virus - Gilead Sciences, announced that the U.S. Food and Drug Administration has approved the supplemental new drug application sNDA for Vemlidy or tenofovir alafenamide, 25 mg tablets as a once-daily treatment for chronic hepatitis B virus HBV infection in pediatric patients 12 years of age and older with compensated liver disease. Vemlidy is a novel, targeted prodrug of tenofovir that was previously approved by the FDA in 2016 as a once-daily treatment for adults with chronic HBV infection with compensated liver disease. It is recommended as a preferred or first-line treatment for adults with chronic HBV with compensated liver disease in guidelines from the American Association for the Study of Liver Diseases AASLDand European Association for the Study of the Liver EASL.

07:48 EDT Lindblad reports FY23 bookings up 23% from FY20 bookings at same point in FY19

07:41 EDT CVS Health raises FY22 Retail/LTC revenue view to $102.7B-$104B - Prior view was $101B-$102.7B. Raises FY22 Retail/LTC adjusted operating income view to $6.66 to $6.72 from $6.54 to $6.64. Backs prescriptions filled outlook of 1%-3% growth.

07:38 EDT Pieris Pharmaceuticals expects cash to fund operations into 2Q24 - Cash, cash equivalents, and investments totaled $69.8 million for the quarter ended September 30, 2022, compared to a cash and cash equivalents balance of $117.8 million for the year ended December 31, 2021. The decrease is due to funding operations in 2022. Including the proceeds from anticipated near-term milestones, the Company believes operations are sufficiently funded into the second quarter of 2024.

07:35 EDT NN's John Buchan to attend White House celebration of skills training - NN announced that President Joe Biden has invited NN, Inc.'s John Buchan, Executive Vice President, Mobile Solutions and Power Solutions, to attend an event celebrating the Infrastructure Talent Pipeline Challenge. The president will host the event honoring businesses, educators, and non-profit organizations that support skills training in their communities.

07:35 EDT CloudMD closes divestment of clinics, Cloud Practice to Well Health - CloudMD Software & Services (DOCRF) announced that it has closed the previously announced divestiture of its primary care clinics and Cloud Practice to Well Health Technologies (WHTCF) for approximately $5.75 million in cash. The closing of this transaction with WELL and the recently announced divestment of the pharmacy assets to Neighbourly Pharmacy, is meaningful progress against CloudMD's objective of divesting its entire Clinics & Pharmacies division. The Company is focused on the growth of its core employer healthcare offering. The Clinics & Pharmacies division, including the practitioner support technology, is not supportive of that growth and does not fit in CloudMD's overall strategy of delivering a higher margin, profitable business long-term. The divestitures provide significant non-dilutive capital and a more focused business.

07:33 EDT CME Group reports ADV up 11% in October to 22.7M contracts - CME Group reported its October 2022 market statistics, showing average daily volume increased 11% to 22.7M contracts during the month, representing the company's highest October volume on record.

07:32 EDT Zynerba announces issuance of new U.S. patent for Zygel - Zynerba Pharmaceuticals announced that the U.S. Patent and Trademark Office has issued Patent No. 11,458,109, titled "Treatment of 22q11.2 Deletion Syndrome With Cannabidiol," which includes claims directed to methods of treating one or more behavioral symptoms of 22q11.2 deletion syndrome with cannabidiol. This new patent, which expires in 2040, is part of an expanding international intellectual property portfolio covering the Company's transdermal cannabidiol product candidate, Zygel. There are currently seven corresponding U.S. patents and one corresponding EU patent related to methods of treating Fragile X syndrome, 22q11.2 deletion syndrome or autism spectrum disorder.

07:28 EDT OraSure's COVID-19 Rapid Test available in Amazon's online store - OraSure Technologies (OSUR) announced that its InteliSwab COVID-19 Rapid Test is now available in Amazon's (AMZN) online store to customers in the United States. The product will be sold and fulfilled by Amazon and eligible for free Amazon Prime shipping. "Amazon has strong consumer reach in the United States, which will help facilitate our goal of broadening access to testing," said Carrie Eglinton Manner, President and CEO of OraSure Technologies. "As we look toward our future strategy, broadening consumer reach through all channels including Amazon will further increase awareness of our products and help empower consumers to manage their own health."

07:27 EDT AIM ImmunoTech receives Orphan Drug Designation for Ampligen - AIM ImmunoTech announced the U.S. Food and Drug Administration, FDA, has granted Orphan Drug Designation to Ampligen for the treatment of Ebola virus disease. Ampligen is AIM's dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. "Receiving Orphan Drug Designation for Ampligen for the treatment of Ebola from the FDA is a testament to the depth and breadth of the potential with Ampligen. We continue to be encouraged by the promising results Ampligen has demonstrated to date across a number of indications where there remains significant unmet need. While Ebola is not a primary focus for the Company at the moment, this provides further validation as well as optionality as we determine the next steps for this program moving forward," commented Thomas Equels, M.S. J.D., Chief Executive Officer of AIM ImmunoTech.

07:25 EDT Charles River: 'Well-positioned' to finish 2022 on strong note

07:24 EDT GXO Logistics to provide warehouse logistics for JD Sports - GXO Logistics (GXO) announced a partnership with JD Sports (JDSPY) for their European omnichannel logistics facility, due to open fully in 2024. "We are excited to expand our partnership with JD Sports to The Netherlands, on top of our current operations with JD Sports' Go Outdoors brand in the United Kingdom," said Richard Cawston, GXO President, Europe. "This agreement with one of the world's leading retailers reinforces our position as an exceptional provider of omnichannel logistics management. We are very much looking forward to supporting JD Sports with our vast experience and expertise in innovative technology and automated ecommerce logistics solutions to drive the best possible consumer experience." GXO will carry out its fulfilment activities from a new 646,000-square-feet distribution facility in centrally located Heerlen, The Netherlands. The facility is expected to create over 1,500 new jobs in the area, once fully operational. Heerlen is a gateway to European markets, and the distribution facility there will serve as a central logistics hub for JD Sports' operations in Continental Europe with 3,300 shops in 32 countries.

07:23 EDT PyroGenesis passes annual audit of 3D printing metal powder business line - PyroGenesis Canada announced that it has passed its annual quality audit for two key international standards: ISO 9001:2015, and AS9100D. The audits encompassed all of PyroGenesis' facilities for the purpose of meeting compliance with the existing quality management designations. The Company also takes this opportunity to provide a brief update on its 3D printing metal powders business line. The Company recently underwent the yearly audit process for two key international standards: ISO 9001:2015, and AS 9100, the latter being a quality management designation specific to the aerospace industry. The audits encompassed all PyroGenesis facilities for the purpose of meeting compliance with the existing quality management designations. The Company is pleased to report 0 Non-Conformances Reports. Additionally, as a result of this audit, the Company's newest facility located at 9371 Wanklyn St. in LaSalle, Quebec, was officially added to the ISO 9001:2015 certification. Separately, PyroGenesis continues on its path to becoming ISO 13485:2016 certified, a Quality Management System designation required by most manufacturers within the medical devices and related services industry. Once obtained, the Company's metal powder offerings will be available to medical device makers as well. Further to its press release dated September 21, 2022, where the Company had announced that an in-house audit of its NexGen metal powder production facility by a global aerospace company. As mentioned, this on-site facility and production audit was a significant step for the Company as it signified the completion of a major part of the final phase of the Client's qualification process. This process has spanned over 18 months of investigative rigor towards becoming an approved supplier of metal powders to the Client and its suppliers. At that time, it was noted that the Client had suggested modifications and adjustments in order to proceed with delivery of final samples of titanium powder for chemical and mechanical testing. We are proud to announce that in less than a month, the Company has completed, as of this writing, over 90% of those suggestions, and is working on completing the remaining 10% before the end of the year. Once completed, the Company will proceed with delivery of final samples of titanium powder for chemical and mechanical testing by the Client. Further to its press release dated July 18, 2022, wherein the Company announced that, in anticipation of expected growth of the European market as well as nearby markets, it is pursuing a strategy to build and operate a metal powder manufacturing facility in Europe. The Company is happy to announce that it has entered early-stage discussions with at least one potential partner for this endeavor. This process is not expected to result in any significant action before 2023. The Company is upgrading and repurposing one of its existing plasma-atomization reactors, previously used for various metal powder R&D activities. By doing so, this reactor will be able to produce commercial metal powders for specialty applications.

07:23 EDT Charles River to divest Avian Vaccine unit for $170M in cash plus payments - The company announced that it has signed a definitive agreement to divest its Avian Vaccine business for approximately $170M in cash with potential contingent payments of up to an additional $30M, subject to certain closing adjustments. The Avian Vaccine business, which is part of Charles River's Manufacturing Solutions segment, produces specific-pathogen-free chicken eggs and associated products and services, principally for avian vaccine manufacturers and researchers. It has approximately 250 employees across approximately 20 sites in the United States. The transaction is expected to close by the end of the year, and will not have a meaningful impact on 2022 revenue and non-GAAP earnings per share. In 2023, the divestiture is expected to reduce annual revenue by approximately $80M and non-GAAP earnings per share by approximately 35c, prior to any benefit from redeploying the proceeds towards other capital priorities.

07:20 EDT Main Street raises dividend 2.3% to 22.5c and announces supplemental dividend - Main Street Capital announced that its Board of Directors declared regular monthly cash dividends of 22.5c per share for each of January, February and March 2023. These monthly dividends, which will be payable pursuant to the table below, total 67.5c per share for the Q1 of FY23 and represent a 2.3% increase from the regular monthly dividends declared for the Q4 and a 4.7% increase from the regular monthly dividends paid in the Q1. In addition to the regular monthly dividends for the Q1 of FY23, the Board of Directors declared a supplemental cash dividend of 10c per share payable in December.

07:20 EDT Vigil announces interim results from its ongoing Phase 1 trial on VGL101 - Vigil Neuroscience announced interim topline results from its ongoing Phase 1 clinical trial of VGL101, its lead product candidate, in healthy volunteers. These interim data support the initiation of a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, ALSP, with a 20 mg/kg dose. "We are very excited by the overall clinical profile of VGL101 seen to date and the progress our team has made in advancing this important program in less than one year's time," said Ivana Magovevi-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. "These interim data, alongside the anticipated initiation of the Phase 2 proof-of-concept trial in ALSP patients this quarter, are key milestones in the development of VGL101 for which we expect important data readouts in 2023." This ongoing trial is a Phase 1 single and multiple ascending dose trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of VGL101. VGL101 was found to be safe and well-tolerated across both the SAD and MAD cohorts dosed. Interim topline results from the ongoing Phase 1 trial of VGL101 include the following: All adverse events were mild in severity with the exception of one moderate AE of dizziness, and all AEs resolved without intervention. No serious adverse events have been reported to date. VGL101 showed dose proportional PK with a favorable half-life and brain penetration. VGL101 achieved dose dependent, durable decreases in levels of sTREM2 in the cerebrospinal fluid demonstrating proof of target engagement. VGL101 20 mg/kg repeat dosing was associated with robust reduction in sTREM2 levels and decreases were still observed 28 days after the third and final dose. VGL101 shows durable increases in sCSF1R levels in the CSF after repeat dosing. The Company continues to dose escalate in its Phase 1 trial in healthy volunteers and has been cleared to initiate a 60 mg/kg cohort in Australia. The Company expects to provide the final data analysis at a future medical conference. Vigil is on track to initiate the VGL101 Phase 2 trial in ALSP patients with a 20 mg/kg dose this quarter.

07:18 EDT Decibel Therapeutics announces submission of CTAs for DB-OTO - Decibel Therapeutics announced the submission of Clinical Trial Applications, CTAs, to the Medicines and Healthcare Products Regulatory Agency, MHRA, in the United Kingdom and the Spanish Agency of Medicines and Medical Devices, AEMPS, for a Phase 1/2 clinical trial in pediatric patients of DB-OTO, a gene therapy product candidate designed to provide durable hearing in individuals with profound congenital hearing loss due to an otoferlin deficiency. "This submission is an important milestone for our DB-OTO product candidate. Over the past several years, we have partnered with leading otolaryngologists and clinical sites in Europe who form a key part of our global clinical development strategy for DB-OTO," said Jonathon Whitton, Au.D., Ph.D., Senior Vice President of Clinical Research and Development at Decibel. "We are excited to work with clinicians and families in the deaf and hard of hearing community to advance our efforts to discover and develop transformative potential treatments for hearing and balance disorders."

07:17 EDT Berry Corporation reaffirms FY22 average daily production 25,500-27,500 boe/d - Cary Baetz, Berry's Executive Vice President and Chief Financial Officer, stated, "We are revising some of our annual guidance ranges due to inflation-driven, higher than budgeted natural gas fuel costs and steel prices, as well as certain field operating costs, coupled with value-adding development, workover and well optimization activity changes beginning mid-year. However, we expect our production rate to grow from the third to fourth quarter. To keep up the momentum into 2023, we are accelerating our development program which is largely responsible for our full year capital guidance change to a range of $140-145 million. With our well-defined Shareholder Return Model, we expect to deliver top tier returns of capital to our shareholders."

07:13 EDT CDW increases cash dividend 18% to 59c per share - CDW Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.59 per common share to be paid on December 9, 2022 to all stockholders of record as of the close of business on November 25, 2022. This amount represents a 18 percent increase over last year's dividend and approximately 25 percent of the trailing-twelve-month Non-GAAP net income through September 30, 2022. Future dividends will be subject to Board of Director approval.

07:12 EDT Altair Engineering promotes Ravi Kunju to Chief Product and Strategy Officer - Altair announced that Ravi Kunju has been named Altair's chief product and strategy officer. In this role, Kunju will be responsible for the strategy and vision of Altair products, which includes facilitating the development, sales, pricing, and marketing of Altair's solutions for industry verticals and business lines. Prior to this role, Kunju has served in several leadership roles within Altair, including senior vice president of business strategy across all business lines, vice president of strategy for enterprise computing, managing director of enterprise computing for the Americas region, and managing director of the U.S. North Central region.

07:11 EDT EyePoint expects cash to fund operations into 2H of 2024 - Cash and investments at September 30, 2022 totaled $157.3 million compared to $171.2 million at June 30, 2022. The company expects the cash, cash equivalents and investments on hand on September 30, 2022 and expected net cash inflows from its product sales will enable it to fund its current and planned operations into the second half of 2024.

07:10 EDT Omega Therapeutics receives FDA orphan designation for OTX-2002 - Omega Therapeutics announced that the U.S.FDA has granted Orphan Drug Designation for OTX-2002, the company's first-in-class epigenomic controller engineered to downregulate c-Myc, for the treatment of hepatocellular carcinoma.

07:05 EDT Oncorus expects cash to fund operations into early 2024 - Cash and cash equivalents and investments totaled $81.5 million as of September 30, 2022 compared to $123.9 million as of December 31, 2021. Oncorus expects its cash, cash equivalents and investments to fund its capital expenditures and operating expenses into early 2024.

07:03 EDT Alkermes announces plans to separate oncology business - Alkermes announced approval by its Board of Directors to explore separating its commercial-stage neuroscience business and development-stage oncology business. The company, together with the Board and external financial and legal advisors, plans to explore a separation of the oncology business into an independent, publicly-traded company (Oncology Co.) as part of an ongoing review of strategic alternatives for the oncology business. "Alkermes will continue to build on our heritage of innovation and excellence in neuroscience. With a strong topline driven by the growth of our proprietary products, a specialized commercial infrastructure in neuropsychiatry and addiction, and proven drug development capabilities, the standalone neuroscience business represents a compelling opportunity to capture operating leverage, drive growth and profitability, and advance new potential medicines for neurological disorders," said Richard Pops, CEO of Alkermes. "With nemvaleukin now in two potential registrational studies, the oncology business has a compelling standalone investment thesis anchored by the potential medical and economic value of this potential first-in-class cancer therapy. We believe separating the oncology business at this time will best support and position nemvaleukin for success, create value for shareholders, and enable efficient advancement of our preclinical pipeline of engineered cytokines." Additional details regarding a separation, including the name of the contemplated Oncology Co., its executive management team and its board of directors, as well as financial details for the two contemplated companies, would be provided at a later date. The separation, if consummated, is expected to be completed in the second half of 2023. Alkermes anticipates Oncology Co. would be located within the company's existing Waltham, Mass. campus. The facilities and research and manufacturing operations in Wilmington, Ohio and Athlone, Ireland will remain with Alkermes. Separation of the two businesses would be subject to customary closing conditions and final approval by Alkermes' Board of Directors. There can be no assurance regarding the ultimate timing or structure of a contemplated separation or that the separation will ultimately occur.

06:58 EDT Ryder acquires Dotcom Distribution, terms not disclosed - Ryder System announces it has acquired Dotcom Distribution, a provider of omnichannel fulfillment and distribution services for high-growth retail and e-commerce brands specializing in health, beauty and cosmetics, and fashion and apparel. With the acquisition, Ryder continues to expand its e-fulfillment network with the opportunity to add an impressive roster of consumer brand names and increase its national footprint with the addition of a 400,000-square-foot multiclient fulfillment facility in Edison, New Jersey. Additionally, Dotcom Distribution's experienced leadership team, including founder and CEO Maria Haggerty, and the company's operations team, totaling approximately 100 full-time employees, will join Ryder to ensure a seamless transition for customers.

06:52 EDT Bed Bath & Beyond CTO Rafeh Masood to step down - In a regulatory 8-K filing, the company states: "On November 1, 2022, Rafeh Masood, Executive Vice President, Chief Customer & Technology Officer of Bed Bath & Beyond Inc. notified the Company of his resignation effective as of December 2, 2022. Mr. Masood's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices or financial statements."

06:46 EDT G1 Therapeutics reports data from first patients in Phase 2 study of trilaciclib - G1 Therapeutics described safety data from the first 18 patients enrolled in its ongoing Phase 2, single arm study of trilaciclib administered prior to the antibody-drug conjugate, or ADC, sacituzumab govitecan-hziy in patients with unresectable locally advanced or metastatic triple-negative breast cancer, or TNBC. These initial data highlight the potential for trilaciclib to meaningfully reduce adverse events related to use of sacituzumab. "Though the data are preliminary, we are seeing encouraging and consistent reductions in the rate of adverse events related to use of sacituzumab govitecan-hziy when trilaciclib is administered prior to the ADC, relative to the previously published single agent safety profile of this ADC, including those related to myelosuppression," said Raj Malik, Chief Medical Officer. "We believe we are seeing on-target effects of trilaciclib in the expected reduction in the rate of myelosuppression and in the rates of diarrhea and potentially alopecia. We will continue to progress this trial and look forward to presenting a more comprehensive data set including initial efficacy results at a medical meeting in the Q2 of 2023." Preliminary Safety Data: Trilaciclib is well tolerated when administered prior to sacituzumab. Initial data on the first 18 patients show a clinically meaningful on-target effect of trilaciclib to reduce the rates of multiple adverse events compared to the previously published sacituzumab govitecan-hziy single agent safety profile from the ASCENT trial, including myelosuppression, and diarrhea and potentially alopecia due to the presence of CDK4/6-expressing cells in the intestinal crypt and hair follicles.

06:38 EDT Estee Lauder raises quarterly dividend 10% to 66c from 60c per share - The Estee Lauder Companies announced a 10% increase in the quarterly dividend on the company's Class A and Class B Common Stock to 66c per share, up from the previous quarterly rate of 60c per share. The dividend will be payable on December 15 to stockholders of record at the close of business on November 30.

06:20 EDT Rogers Corporation 'currently evaluating all options' in response to DuPont - Rogers Corporation (ROG) issued the following statement in response to DuPont's (DD) notice of termination of the definitive merger agreement entered into by Rogers and DuPont on November 1, 2021: "Rogers is currently evaluating all options to determine the best path forward in response to DuPont's notice. Rogers remains an exceptional company, and the team continues to execute on our successful growth strategy. Our strong competitive position innovating across fast-growing markets, including EV/HEV, is underscored by continuing design wins, broad customer enthusiasm and a robust pipeline of opportunities."

06:01 EDT GSK raises FY22 sales growth view to 8%-10% from 6%-8% - Reflecting the momentum of the business performance in the year to date, GSK now expects 2022 sales to increase between 8%-10% and Adjusted operating profit to increase between 15%-17%, excluding any contributions from COVID-19 solutions. Adjusted Earnings per share is expected to grow around 1% lower than Operating Profit. GSK said: "We have delivered a strong nine-month performance ahead of our full-year guidance. In the fourth quarter, we anticipate continued strong sales growth and a relatively higher rate of R&D spending, reflecting the dynamics of prior year comparisons, in-year phasing, and continued targeted commercial investment." GSK added: "We continue to see evidence of healthcare systems recovering and now expect full-year sales of Specialty Medicines to increase low double-digit percentage at CER excluding Xevudy sales and sales of General Medicines to be broadly flat, primarily reflecting the increased genericisation of established Respiratory medicines. Vaccines sales, excluding COVID-19 solutions, are expected to grow mid to high-teens percentage at CER for the full year. Specifically, for Shingrix, we expect strong double-digit growth and record annual sales in 2022, based on strong demand in existing markets and continued geographical expansion."